CryoPort (NASDAQ:CYRX) Insider Sells $10,969.38 in Stock

CryoPort, Inc. (NASDAQ:CYRX) insider Mark Sawicki sold 1,341 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $8.18, for a total transaction of $10,969.38. Following the completion of the transaction, the insider owned 102,356 shares in the company, valued at $837,272.08. This represents a 1.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

CryoPort Stock Down 4.8%

Shares of NASDAQ CYRX opened at $7.82 on Friday. The firm’s fifty day moving average is $8.77 and its 200 day moving average is $9.30. CryoPort, Inc. has a 52 week low of $4.63 and a 52 week high of $11.45. The company has a market cap of $389.91 million, a price-to-earnings ratio of 5.92 and a beta of 1.69.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $45.45 million for the quarter, compared to analysts’ expectations of $42.92 million. CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. Equities research analysts anticipate that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Basepoint Wealth LLC purchased a new stake in shares of CryoPort in the 4th quarter worth about $34,000. Tower Research Capital LLC TRC increased its position in shares of CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after buying an additional 4,375 shares during the period. Whittier Trust Co. of Nevada Inc. purchased a new position in shares of CryoPort during the third quarter valued at about $53,000. ProShare Advisors LLC bought a new position in CryoPort in the second quarter worth about $75,000. Finally, AlphaQuest LLC bought a new position in CryoPort in the third quarter worth about $79,000. 92.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CYRX has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Wall Street Zen downgraded CryoPort from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, Needham & Company LLC increased their price objective on CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.94.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.